Best selling products
84.52112.7 SAVE 25%
84.52112.7 SAVE 25%Save 25%
19.526 SAVE 25%
19.526 SAVE 25%Save 25%
14.2619.01 SAVE 25%
14.2619.01 SAVE 25%Save 25%
14.2619.01 SAVE 25%
14.2619.01 SAVE 25%Save 25%
14.2619.01 SAVE 25%
14.2619.01 SAVE 25%Save 25%
14.2619.01 SAVE 25%
14.2619.01 SAVE 25%Save 25%
Best selling products
74.18148.35 SAVE 50%
74.18148.35 SAVE 50%Save 50%
62.277.75 SAVE 20%
62.277.75 SAVE 20%20% Off
98.85197.69 SAVE 50%
98.85197.69 SAVE 50%Save 50%
87.95188.99 SAVE 53%
Best selling products
291.53448.5 SAVE 35%
291.53448.5 SAVE 35%Save 35%
توصيل مجاني
57.5115 SAVE 50%
57.5115 SAVE 50%Save 50%
94.9598.46 SAVE <img style='max-width: 25px;max-height:25px;display: inline-block' src='https://ghc-uat3.storehippo.com/s/6707cfc676791e0024a38a81/ms.files/newsymbol-60x60.png'>3.51
94.9598.46 SAVE <img style='max-width: 25px;max-height:25px;display: inline-block' src='https://ghc-uat3.storehippo.com/s/6707cfc676791e0024a38a81/ms.files/newsymbol-60x60.png'>3.51
194.5389 SAVE 50%
194.5389 SAVE 50%Save 50%
Best selling products
367.5612.5 SAVE 40%
367.5612.5 SAVE 40%40% Off
210.75351.25 SAVE 40%
210.75351.25 SAVE 40%40% Off
Best selling products
4386 SAVE 50%
4386 SAVE 50%Save 50%
SAMBUCOL
66a7d1fdb0e46d3d62c29a19
22.3744.75 SAVE 50%
22.3744.75 SAVE 50%Save 50%
41.2555 SAVE 25%
41.2555 SAVE 25%Save 25%
Save 25%
41.2555 SAVE 25%
41.2555 SAVE 25%Save 25%
Whites Exclusive
Recently viewed
Product Description:
CHAM PIX is indicated for smoking cessation in adults
How to use:
The recommended dose is 1 mg varenicline twice daily
Following a 1-week titration as follows: Days 1-3: 0.5 mg once daily, Days 4-7: 0.5 mg twice daily, Day 8 (End of treatment): 1 mg twice daily.
The patient should set a date to stop smoking.
CHAM PIX dosing should usually start at 1-2 weeks before this date.
Patients should be treated with CHAM PIX for 12 weeks.
Caution & Warnings:
Hypersensitivity to the active substance or to any of the excipients.Clinical signs included swelling of the face, mouth (tongue, lips, and gums), neck (throat and larynx) and extremities.
Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHAMP IX, may alter the pharmacokinetics or pharmacodynamics of some medicines, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).
Neuropsychiatric symptoms: suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with CHAMPIX in the post-marketing experience.
Depressed mood, rarely including suicide attempt, may be a symptom of nicotine withdrawal.
CHAM PIX should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Treatment discontinuation: At the end of treatment, discontinuation of CHAM PIX was associated with an increase in irritability, urge to smoke, depression, and/or insomnia in up to 3% of patients.
Cardiovascular events: notify your doctor of new or worsening cardiovascular symptoms
pregnancy and lactation:
Pregnancy: A moderate amount of data on pregnant women indicated no malformative or fetal/neonatal toxicity of varenicline. Animal studies have shown reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of varenicline during pregnancy.
Breast-feeding: It is unknown whether varenicline is excreted in human breast milk. Animal studies suggest that varenicline is excreted in breast milk. A decision on
whether to continue/discontinue breast-feeding or to continue/discontinue therapy with CHAMPIX should be made taking into account the benefits of breast-feeding to the child and the benefits of CHAMPIX therapy to the woman.
Patients with renal impairment:
No dosage adjustment is necessary for patients with mild to moderate renal impairment.
For patients with severe renal impairment, the recommended dose of CHAM PIX is 1 mg once daily.
Dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily.
Based on insufficient clinical experience with CHAMPIX in patients with end-stage renal disease, treatment is not recommended in this patient population.
Patients with hepatic impairment:
No dosage adjustment is necessary for patients with hepatic
impairment.
Pediatric population:
The safety of CHAMPIX in children or adolescents below 18 years have not yet been established
Ingredients:
varenicline 1 mg.
Product Description:
CHAM PIX is indicated for smoking cessation in adults
How to use:
The recommended dose is 1 mg varenicline twice daily
Following a 1-week titration as follows: Days 1-3: 0.5 mg once daily, Days 4-7: 0.5 mg twice daily, Day 8 (End of treatment): 1 mg twice daily.
The patient should set a date to stop smoking.
CHAM PIX dosing should usually start at 1-2 weeks before this date.
Patients should be treated with CHAM PIX for 12 weeks.
Caution & Warnings:
Hypersensitivity to the active substance or to any of the excipients.Clinical signs included swelling of the face, mouth (tongue, lips, and gums), neck (throat and larynx) and extremities.
Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHAMP IX, may alter the pharmacokinetics or pharmacodynamics of some medicines, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).
Neuropsychiatric symptoms: suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with CHAMPIX in the post-marketing experience.
Depressed mood, rarely including suicide attempt, may be a symptom of nicotine withdrawal.
CHAM PIX should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Treatment discontinuation: At the end of treatment, discontinuation of CHAM PIX was associated with an increase in irritability, urge to smoke, depression, and/or insomnia in up to 3% of patients.
Cardiovascular events: notify your doctor of new or worsening cardiovascular symptoms
pregnancy and lactation:
Pregnancy: A moderate amount of data on pregnant women indicated no malformative or fetal/neonatal toxicity of varenicline. Animal studies have shown reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of varenicline during pregnancy.
Breast-feeding: It is unknown whether varenicline is excreted in human breast milk. Animal studies suggest that varenicline is excreted in breast milk. A decision on
whether to continue/discontinue breast-feeding or to continue/discontinue therapy with CHAMPIX should be made taking into account the benefits of breast-feeding to the child and the benefits of CHAMPIX therapy to the woman.
Patients with renal impairment:
No dosage adjustment is necessary for patients with mild to moderate renal impairment.
For patients with severe renal impairment, the recommended dose of CHAM PIX is 1 mg once daily.
Dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily.
Based on insufficient clinical experience with CHAMPIX in patients with end-stage renal disease, treatment is not recommended in this patient population.
Patients with hepatic impairment:
No dosage adjustment is necessary for patients with hepatic
impairment.
Pediatric population:
The safety of CHAMPIX in children or adolescents below 18 years have not yet been established
Ingredients:
varenicline 1 mg.
Product Description:
CHAM PIX is indicated for smoking cessation in adults
How to use:
The recommended dose is 1 mg varenicline twice daily
Following a 1-week titration as follows: Days 1-3: 0.5 mg once daily, Days 4-7: 0.5 mg twice daily, Day 8 (End of treatment): 1 mg twice daily.
The patient should set a date to stop smoking.
CHAM PIX dosing should usually start at 1-2 weeks before this date.
Patients should be treated with CHAM PIX for 12 weeks.
Caution & Warnings:
Hypersensitivity to the active substance or to any of the excipients.Clinical signs included swelling of the face, mouth (tongue, lips, and gums), neck (throat and larynx) and extremities.
Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHAMP IX, may alter the pharmacokinetics or pharmacodynamics of some medicines, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).
Neuropsychiatric symptoms: suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with CHAMPIX in the post-marketing experience.
Depressed mood, rarely including suicide attempt, may be a symptom of nicotine withdrawal.
CHAM PIX should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Treatment discontinuation: At the end of treatment, discontinuation of CHAM PIX was associated with an increase in irritability, urge to smoke, depression, and/or insomnia in up to 3% of patients.
Cardiovascular events: notify your doctor of new or worsening cardiovascular symptoms
pregnancy and lactation:
Pregnancy: A moderate amount of data on pregnant women indicated no malformative or fetal/neonatal toxicity of varenicline. Animal studies have shown reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of varenicline during pregnancy.
Breast-feeding: It is unknown whether varenicline is excreted in human breast milk. Animal studies suggest that varenicline is excreted in breast milk. A decision on
whether to continue/discontinue breast-feeding or to continue/discontinue therapy with CHAMPIX should be made taking into account the benefits of breast-feeding to the child and the benefits of CHAMPIX therapy to the woman.
Patients with renal impairment:
No dosage adjustment is necessary for patients with mild to moderate renal impairment.
For patients with severe renal impairment, the recommended dose of CHAM PIX is 1 mg once daily.
Dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily.
Based on insufficient clinical experience with CHAMPIX in patients with end-stage renal disease, treatment is not recommended in this patient population.
Patients with hepatic impairment:
No dosage adjustment is necessary for patients with hepatic
impairment.
Pediatric population:
The safety of CHAMPIX in children or adolescents below 18 years have not yet been established
Ingredients:
varenicline 1 mg.
